The Rare Disease Paradox: When Science Meets Insurer's Arithmetic The story of Mason Henderson is a heartbreaking reminder that even in the era of precision medicine, the pursuit of life saving treatments can be hindered by the complexities of insurance coverage and regulatory frameworks.
His case highlights the devastating consequences for patients with rare diseases when science, policy, and corporate interests intersect. Mason was diagnosed with a rare form of brain cancer at 20 years old.
Despite undergoing surgery, radiation, and chemotherapy, his cancer spread to his spinal cord. His doctors recommended treatment with Lynparza, an FDA approved drug that had shown promise in clinical trials.